粤港湾控股(01396)发布公告，公司股本中每股面值0.10港元的股份于香港联合交易所有限公司(联交所) 主板买卖的每手买卖单位将由8000股股份更改为2000股股份，自2025年11月24日(星期一)上午九时正起 生效(更改每手买卖单位)。 ...

智通财经APP讯，粤港湾控股(01396)发布公告，公司股本中每股面值0.10港元的股份于香港联合交易所 有限公司(联交所)主板买卖的每手买卖单位将由8000股股份更改为2000股股份，自2025年11月24日(星期 一)上午九时正起生效(更改每手买卖单位)。 ...

格隆汇11月3日丨粤港湾控股(01396.HK)宣布，公司股本中每股面值0.10港元的股份于联交所主板买卖 的每手买卖单位将由8,000股股份更改为2,000股股份，自2025年11月24日(星期一)上午九时正起生效。 ...

Core Viewpoint - The company has secured orders for AI server immersion liquid cooling cabinets from Taiwanese manufacturers, with deliveries expected to begin in November 2025, indicating a strong demand for AI solutions in the market [1][2] Group 1: Company Developments - The company's subsidiary, Precision Industries, has completed technical validation for immersion liquid cooling cabinets and is set to design, develop, and produce these products according to customer specifications [1] - A joint venture has been established with Forman Technology to expand the AI server liquid cooling system business, with a production facility in Jiaxing already capable of small-batch production and expected to reach mass production by December 2025 [1][2] Group 2: Market Trends and Opportunities - The global AI server liquid cooling system market is anticipated to experience rapid growth due to increasing demand for AI solutions across various industries [2] - The company has a strong foothold in the automotive sector with advanced development and production technologies for battery box structural components and liquid cooling plates, ensuring high-performance and reliable production capabilities [2] - The partnership with Forman Technology, which has over 20 years of experience in liquid cooling system products, is expected to enhance the company's technological capabilities and production efficiency [2]

和黄医药研发负责人兼首席医学官石明博士表示："满足癌症和免疫疾病领域关键未被满足的医学需求 是和黄医药的使命所在，驱动着我们持续致力推进创新疗法。ATTC平台有望重新定义癌症精准治疗， 依托我们坚实的产品管线和合作策略，我们有信心能够为全球患者提供具有潜在变革性的癌症和免疫疾 病治疗方案。" 智通财经APP讯，和黄医药(00013)发布公告，于2025年10月31日举行的投资者会议中分享最新关键研发 和业务进展。此次活动重点展示了和黄医药在推进创新癌症和免疫疾病治疗方面的最新进展，包括介绍 其新一代抗体靶向偶联药物(ATTC)平台，以及后期管线候选药物的最新进展。 ...

智通财经APP讯，中通快递-W(02057)发布公告，该公司于2025年10月31日斥资708.55万美元回购38.33 万股股份，每股回购价格为18.19-18.63美元。 ...

格隆汇11月3日丨和誉-B(02256.HK)宣布，其口服小分子PD-L1抑制剂ABSK043与上海艾力斯医药科技 股份有限公司("艾力斯")KRAS G12C抑制剂戈来雷塞联合用于治疗携带KRAS G12C突变的非小细胞肺 癌("NSCLC")的II期临床研究已完成首例患者给药。 ...

格隆汇11月3日丨中通快递-W(02057.HK)发布公告，2025年10月31日耗资708.55万美元回购38.33万股， 每股回购价18.19-18.63美元。 ...

Core Viewpoint - The company has secured orders for AI server immersion liquid cooling cabinets from Taiwanese manufacturers, with deliveries expected to begin in November 2025, indicating a strong demand for AI solutions in the market [1][2] Group 1: Company Developments - The company's subsidiary, Precision Industries, has completed technical validation for immersion liquid cooling cabinets and is set to design, develop, and produce these products according to customer specifications [1] - A joint venture has been established with Forman Technology to expand the AI server liquid cooling system business, with a production facility in Jiaxing already capable of small-batch production [1] - The company has also passed technical validation for a splitter from another Taiwanese AI server liquid cooling system manufacturer, with the first batch of products expected to be delivered by the end of December 2025 [1] Group 2: Industry Trends - The global AI server liquid cooling system market is anticipated to experience rapid growth due to increasing demand for AI solutions across various industries [2] - The company has established a strong global production capacity in the automotive sector, particularly in battery box structural components and liquid cooling plates, ensuring high-performance and reliable production [2] - The company is actively exploring new growth avenues in emerging fields such as AI, robotics, low-altitude economy, and smart mobility, supported by a long-term partnership with leading Taiwanese server manufacturers [2]

格隆汇11月3日丨和黄医药(00013.HK)于2025年10月31日举行的投资者会议中分享最新关键研发和业务 进展。此次活动重点展示了和黄医药在推进创新癌症和免疫疾病治疗方面的最新进展，包括介绍其新一 代抗体靶向偶联药物("ATTC")平台，以及后期管线候选药物的最新进展。 和黄医药研发负责人兼首席医学官石明博士表示："满足癌症和免疫疾病领域关键未被满足的医学需求 是和黄医药的使命所在，驱动着我们持续致力推进创新疗法。ATTC平台有望重新定义癌症精准治疗， 依托我们坚实的产品管线和合作策略，我们有信心能够为全球患者提供具有潜在变革性的癌症和免疫疾 病治疗方案。" ...